AP20187

AP20187

CAT N°: 36808
Price:

From 132.00 112.20

AP20187 is a chemical inducer of dimerization (CID) for FK506 binding protein (FKBP) fusion proteins.{67124} It increases expression of the genes encoding DNA damage-inducible transcript 3 (Ddit3) and growth arrest and DNA damage-inducible protein 34 (Gadd34) in primary mouse neonatal glial cells when used at a concentration of 0.1 nM.{67123} It increases apoptosis induced by adenoviral vectors expressing conditional caspase-1 (Ad-G/iCasp1) in LNCaP and PC3 human prostate, as well as TRAMP-C2 and TRAMP-C2G murine prostate, cancer cells in a concentration-dependent manner.{67124} AP20187 (2 mg/kg), when used in combination with Ad-G/iCasp1, induces apoptosis and reduces tumor volume in a TRAMP-C2 murine prostate cancer model. It induces apoptosis in p16Ink4a-positive senescent cells and increases lifespan in ATTAC transgenic mice expressing FKBP-Casp8 and GFP when administered at a dose of 2 µg/g twice per week.{67122} AP20187 delays tumorigenesis and reduces glomerulosclerosis and kidney dysfunction in the same mouse model.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 2-piperidinecarboxylic acid, (2S,2?S)-1-[(2S)-1-oxo-2-(3,4,5-trimethoxyphenyl)butyl]-2,2?-[[2-[(dimethylamino)methyl]-1,3-propanediyl]bis[imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylene[(1R)-3-(3,4-dimethoxyphenyl)propylidene]]] ester
  • Correlated keywords
    • AP-20187 FK-506 Ddit-3 Gadd-34 AdG/iCasp1 Ad-G iCasp1 iCasp-1 PC-3 TRAMPC2 TRAMPC2G p16-Ink4a
  • Product Overview:
    AP20187 is a chemical inducer of dimerization (CID) for FK506 binding protein (FKBP) fusion proteins.{67124} It increases expression of the genes encoding DNA damage-inducible transcript 3 (Ddit3) and growth arrest and DNA damage-inducible protein 34 (Gadd34) in primary mouse neonatal glial cells when used at a concentration of 0.1 nM.{67123} It increases apoptosis induced by adenoviral vectors expressing conditional caspase-1 (Ad-G/iCasp1) in LNCaP and PC3 human prostate, as well as TRAMP-C2 and TRAMP-C2G murine prostate, cancer cells in a concentration-dependent manner.{67124} AP20187 (2 mg/kg), when used in combination with Ad-G/iCasp1, induces apoptosis and reduces tumor volume in a TRAMP-C2 murine prostate cancer model. It induces apoptosis in p16Ink4a-positive senescent cells and increases lifespan in ATTAC transgenic mice expressing FKBP-Casp8 and GFP when administered at a dose of 2 µg/g twice per week.{67122} AP20187 delays tumorigenesis and reduces glomerulosclerosis and kidney dysfunction in the same mouse model.

We also advise you